Assuming that hGH has a less relevant influence on the glucose metabolism pathway than IGF-1, these results support the utilization of hGH in clinical trials in place of IGF-1 to reduce the risk of hypoglycemia. The gene discussed is IGF1; the disease is Hypoglycemia.